|1.||Ehrenberger, Klaus: 5 articles (05/2009 - 01/2002)|
|2.||Chen, Zhiqiang: 4 articles (12/2006 - 01/2003)|
|3.||Ruan, Runsheng: 4 articles (12/2006 - 01/2003)|
|4.||Duan, Maoli: 4 articles (12/2006 - 01/2003)|
|5.||Ulfendahl, Mats: 4 articles (12/2006 - 01/2003)|
|6.||Nohl, Hans: 2 articles (01/2005 - 01/2003)|
|7.||Bieberschulte, Werner: 2 articles (01/2005 - 01/2003)|
|8.||Tan, Luke: 2 articles (11/2004 - 10/2003)|
|9.||Stanisz, Isabella: 1 article (11/2015)|
|10.||Enzenhofer, Elisabeth: 1 article (11/2015)|
03/01/2004 - "The values for tinnitus loudness, level of irritation caused by the tinnitus and subjective effectiveness of the therapy - measured by means of the visual analog scale (VAS) - showed no significant change, although the most marked improvement was indicated for caroverine. "
11/01/1997 - "In total, 60 patients with inner ear tinnitus of assumed cochlear-synaptic pathophysiology were included in the study: after computerized randomization, 30 were treated with caroverine and 30 with placebo. "
11/01/1997 - "This study was performed to examine whether a single infusion of caroverine, a quinoxaline-derivative, can be used successfully in the treatment of inner ear tinnitus. "
01/01/2005 - "In a representative patient cohort, the probability of a long-lasting tinnitolytic effect of lipophilic eardrops containing 1% Caroverine as their active ingredient gained in significance, crossing from low-intensity levels to high-intensity levels of individual tinnitus sensations. "
01/01/2005 - "This prospective study, which conformed with good clinical practice (GCP-conform), tested the concept that the topical transtympanic administration of the quinoxaline derivative Caroverine promises a new approach to the treatment of tinnitus. "
02/01/1996 - "5. Caroverine attenuated this hypoxia-induced vigilance decrement in a dose- and time-dependent manner 6-8 h after 80 mg and 2-8 h after 120 mg. 6. Hypoxic hypoxidosis induced a deterioration of memory and attention variability, which was mitigated by 80 and 120 mg caroverine. "
02/01/1996 - "On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia."
|3.||Olfaction Disorders (Anosmia)
|4.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/01/1987 - "We present a randomized double-blind study on the efficacy of caroverine in the treatment of alcohol withdrawal symptoms. "
10/02/2003 - "Comparable to the anti-craving compound acamprosate, caroverine reduces alcohol withdrawal symptoms by an antagonism at ionotropic glutamate receptors and a blockade of calcium channels. "
|5.||Noise-Induced Hearing Loss (Acoustic Trauma)
12/01/2006 - "Physiological and morphological assessments indicated that low-dose and long-term caroverine delivery might be a new approach to protect against impulse noise-induced hearing loss. "
12/01/2006 - "Low-dose, long-term caroverine administration attenuates impulse noise-induced hearing loss in the rat."
11/01/2004 - "Caroverine was found to offer significant protection of the cochlear function against noise-induced hearing loss."
01/01/2003 - "The findings suggest that local application of caroverine on the RWM for the treatment of excitotoxicity-related inner ear diseases, such as tinnitus and noise-induced hearing loss, might be both safe and more efficacious while avoiding high blood and CSF caroverine levels seen with systemic administration."
03/01/1995 - "Magnesium and the quinoxaline derivative Caroverine, which have already been tested in humans, exhibit a statistically significant otoneuroprotective action in noise-induced hearing loss and tinnitus. "
|1.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|3.||Calcium Channels (Calcium Channel)
|4.||Glutamate Receptors (Glutamate Receptor)
|5.||Reactive Oxygen Species (Oxygen Radicals)
|6.||Ionotropic Glutamate Receptors
|10.||Thioctic Acid (Lipoic Acid)